302-41-0 Usage
Description
Piritramide, a synthetic opioid, is an off-white low melting solid that is commonly used in Germany and Austria for the analgesia of pediatric patients.
Uses
Used in Pharmaceutical Industry:
Piritramide is used as an analgesic agent for the management of moderate to severe pain in pediatric patients. Its efficacy in providing pain relief makes it a valuable component in the treatment of various painful conditions in children.
Originator
Dipidolor ,Janssen W. ,Germany,1969
Manufacturing Process
A mixture of 84 parts of 3,3-diphenyl-3-cyanopropyl bromide, 41 parts of 4piperidino-4-piperidinecarboxamide, 64 parts of sodium carbonate, a small amount of potassium iodide and 1,200 parts of anhydrous toluene was stirred, and heated under reflux for 48 hours. At the end of this time the reaction mixture was allowed to cool to room temperature, and 500 parts of water were added. The resultant precipitate was removed by filtration, and triturated with diisopropyl ether. The crystalline material thus obtained was removed by filtration, and recrystallized from 320 parts of acetone, to give 1-(3,3diphenyl-3-cyanopropyl)-4-piperidino-4-piperidinecarboxamide, melting at about 149°C to 150°C.
Therapeutic Function
Analgesic
Check Digit Verification of cas no
The CAS Registry Mumber 302-41-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,0 and 2 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 302-41:
(5*3)+(4*0)+(3*2)+(2*4)+(1*1)=30
30 % 10 = 0
So 302-41-0 is a valid CAS Registry Number.
InChI:InChI=1/C27H34N4O/c28-22-26(23-10-4-1-5-11-23,24-12-6-2-7-13-24)14-19-30-20-15-27(16-21-30,25(29)32)31-17-8-3-9-18-31/h1-2,4-7,10-13H,3,8-9,14-21H2,(H2,29,32)
302-41-0Relevant articles and documents
Combination of selected opioids with muscarine antagonists for treating urinary incontinence
-
, (2008/06/13)
Active compound combinations of compounds of group A, particularly opioids, and compounds of group B, particularly anti-muscarine agents and other substances suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.